ZS Pharma Announces Positive Results From The Extended Treatment Phase Of Its Phase 3 Trial Of ZS-9 In Patients With Hyperkalemia
1/13/2014 11:14:32 AM
COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Extended Treatment Phase of ZS003, its pivotal Phase 3 trial of ZS-9. ZS-9 is a novel, investigational treatment for hyperkalemia. Top-line analyses of the safety and efficacy results showed that the trial met the pre-specified endpoint for the 12-day Extended Treatment Phase, demonstrating that both 5g and 10g of ZS-9 given once-daily maintained a statistically and clinically significant reduction in serum potassium (K+) relative to placebo. ZS-9 was also well-tolerated with a gastrointestinal (GI) adverse event rate and an overall adverse event rate similar to placebo across all doses tested.
Help employers find you! Check out all the jobs and post your resume.
comments powered by